MedWatch

Clinical breakthrough for prostate cancer drug

A rival candidate drug to Bavarian Nordic’s Prostvac has shown highly promising results in a phase 3 study. A Danish professor calls the results “a clinical breakthrough”.

One in ten men are diagnosed with prostate cancer at some point in their lives, and each year approximately 4000 men receive the diagnosis. But now the American company Johnson & Johnson brings good news to these patients.

At the recent ASCO convention the pharmaceutical company published results from a phase III study with their prostate cancer drug Zytiga.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier